RFK Jr. bashes Ozempic buzz and Novo Nordisk profits
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply must be the solution to the obesity epidemic
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Senate panel questions Novo Nordisk CEO over decision to discontinue this popular insulin
Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health insurers.
Novo Nordisk CEO Grilled by Congress Over Price of Ozempic
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.
Novo Nordisk CEO Faces Senate Questions Over High Prices Of Ozempic And Wegovy In US
Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Senators question Novo Nordisk CEO on price of Ozempic
Lawmakers want to know why Americans pay so much more than other countries for weight loss drugs
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Evotec and Novo Nordisk in technology development partnership
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on ...
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
FiercePharma10h
Novo Nordisk scolded by UK drug marketing watchdog over sponsorship of weight loss services
Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down ...
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...
EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a technology development ...
Evotec and Novo Nordisk forge technology development partnership
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...
Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
The results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help ...